Table II.
Correlation of serum C-C motif chemokine ligand 11 levels with clinicopathological features of breast cancer in the hospital cohort.
| CCL11 expression | |||
|---|---|---|---|
| Clinicopathological feature | High (n=50) | Low (n=50) | P-value |
| Age (years) | 0.6853 | ||
| <58 | 30 | 28 | |
| ≥58 | 20 | 22 | |
| Tumor diameter (cm) | 0.0394 | ||
| <2 | 26 | 36 | |
| ≥2 | 24 | 14 | |
| Tumor stage | 0.0302 | ||
| I | 9 | 20 | |
| II | 30 | 27 | |
| III | 8 | 2 | |
| IV | 3 | 1 | |
| Histologic grade | 0.5860 | ||
| I | 7 | 11 | |
| II | 25 | 26 | |
| III | 14 | 11 | |
| IV | 4 | 2 | |
| Histology | 0.6701 | ||
| Ductal | 40 | 43 | |
| Lobular | 8 | 5 | |
| Other | 2 | 2 | |
| ER status | 0.0211 | ||
| Positive | 38 | 27 | |
| Negative | 12 | 23 | |
| PR status | 0.8399 | ||
| Positive | 29 | 28 | |
| Negative | 21 | 22 | |
| HER2 status | 0.8595 | ||
| Positive | 25 | 20 | |
| Negative | 25 | 30 | |
The χ2 test was used to identify differences between the groups. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor type 2.